lasmecabtagene timgedleucel
Generic: Lasmecabtagene Timgedleucel
lasmecabtagene timgedleucel: 1 clinical trial tracked.
lasmecabtagene timgedleucel evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about lasmecabtagene timgedleucel, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Primary endpoint: Incidence of AE/SAE/DLT [Safety and Tolerability]
Interventionalopen52 targetStarted 2019-10Completion 2026-0619 sites · France, United StatesCellectis S.A.